Clinical Utility of Next Generation Sequencing in Concurrent EBUS-TBNA and Liquid Biopsies in NSCLC
Blood and tissue biopsies together catch more actionable mutations than either alone, improving precision testing for lung cancer.
This prospective study of 199 NSCLC patients showed tissue biopsy via EBUS-TBNA detected 15% more clinically actionable mutations than concurrent liquid biopsy, yet 3.5% of patients had mutations only in blood. The findings define liquid biopsy as complementary—not equivalent—to tissue biopsy for NGS in NSCLC and highlight the need for improved sensitivity and turnaround time.
What the study was
- Study design
- Prospective observational cohort study
- Population
- 199 NSCLC patients undergoing concurrent EBUS-TBNA tissue biopsy and liquid biopsy for NGS
- Sample size
- 199
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- American journal of respiratory and critical care medicine
Why it surfaced
Prospective 199-patient AJRCCM study comparing tissue vs. liquid biopsy NGS yields; provides clinically actionable evidence defining complementary roles of both approaches.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.